Brookfield Corp’s BioMarin Pharmaceuticals BMRN Stock Holding History

Brookfield Corp’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,798	Closed	-$1.63M	–	172
2023 Q2	$1.63M	Sell	18,798 -118,545	-86%	-$11.2M	0.01%	424
2023 Q1	$13.4M	Sell	137,343 -38,302	-22%	-$3.97M	0.05%	136
2022 Q4	$18.2M	Buy	175,645 +29,330	+20%	+$2.75M	0.07%	100
2022 Q3	$12.4M	Sell	146,315 -12,541	-8%	-$1.12M	0.05%	139
2022 Q2	$13.2M	Sell	158,856 -31,272	-16%	-$2.49M	0.06%	117
2022 Q1	$14.7M	Buy	190,128 +95,426	+101%	+$7.98M	0.05%	118
2021 Q4	$8.37M	Buy	94,702 +26,930	+40%	+$2.22M	0.03%	147
2021 Q3	$5.24M	Sell	67,772 -14,255	-17%	-$1.12M	0.02%	214
2021 Q2	$6.84M	Buy	82,027 +10,839	+15%	+$859K	0.03%	174
2021 Q1	$5.38M	Buy	71,188 +18,281	+35%	+$1.49M	0.03%	157
2020 Q4	$4.64M	Buy	+52,907	New	+$4.19M	0.02%	170

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Brookfield Corp's BMRN Position: Q3 2023 in Review

Brookfield Corp sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 18,798 shares — an estimated $1.63M sold.

Brookfield Corp first reported a position in BMRN in Q4 2020 and held it in 11 quarters. The position peaked at $18.2M in Q4 2022. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Brookfield Corp reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Brookfield Corp sold 18,798 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $1.63M.
Brookfield Corp first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 11 quarters.
Brookfield Corp's BioMarin Pharmaceuticals position peaked at $18.2M in Q4 2022.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.